Azenta, Inc. (AZTA) Stock Analysis
Healthcare · Medical Instruments & Supplies · NasdaqGS
Azenta, Inc. (AZTA) posted $593.82M in revenue for fiscal 2025 (down 9.5% year over year), with a net loss of $59.50M, and has compounded revenue about 8.9%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Azenta, Inc.
Azenta, Inc. has grown revenue from $434.01M to $593.82M over the last 10 fiscal years, compounding about 8.9% a year. The most recent year was down 9.5%, so growth has cooled from its longer-run pace.
Net margin sits at -10%, up 15 points year over year on a 45.5% gross margin.
At today's valuation the market is pricing in roughly 11.9% annual free-cash-flow growth. The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Azenta, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Azenta, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $434.01M | $527.50M | $631.56M | $334.18M | $388.54M | $513.70M | $555.50M | $665.07M | $656.32M | $593.82M |
| Gross profit | $156.69M | $198.89M | $246.08M | $134.60M | $172.15M | $243.81M | $255.58M | $239.21M | $254.62M | $270.28M |
| Net income | $-69.48M | $62.61M | $116.58M | $437.42M | $64.85M | $110.75M | $2.13B | $-14.26M | $-164.17M | $-59.50M |
| Net margin | -16.0% | 11.9% | 18.5% | 130.9% | 16.7% | 21.6% | 384.0% | -2.1% | -25.0% | -10.0% |
Source: Azenta, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Azenta, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -10.0%).
What growth is priced into AZTA stock?
At today's market cap of $1.04B, Azenta, Inc. is priced for free-cash-flow growth of about 11.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $38.32M from the FY ending 2025-09-30). For comparison, revenue 8.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Azenta, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AZTA in your portfolio →
Azenta, Inc. financial history by metric
Compare Azenta, Inc. with peers
About Azenta, Inc.
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Azenta, Inc. — frequently asked questions
What is Azenta, Inc.'s revenue?
Azenta, Inc. (AZTA) reported revenue of $593.82M for fiscal year 2025, down 9.5% from the prior year, according to its SEC filings.
Is Azenta, Inc. profitable?
No — AZTA reported a net loss of $-59.50M in fiscal 2025.
What is AZTA's P/E ratio?
Azenta, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Azenta, Inc. growing?
AZTA's revenue grew at roughly 8.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Azenta, Inc. have?
As of fiscal year 2025, AZTA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Azenta, Inc.'s gross margin?
AZTA's gross margin was 45.5% in fiscal 2025 — gross profit of $270.28M on revenue of $593.82M.
What is Azenta, Inc.'s market cap?
Azenta, Inc. (AZTA) has a market capitalization of about $1.04B, based on the latest data in our nightly-refreshed cache.
When does Azenta, Inc.'s fiscal year end?
AZTA's fiscal year ends in September. Its most recent annual filing covers the fiscal year ending 2025-09-30.
What growth is priced into AZTA stock?
At today's market cap of $1.04B, Azenta, Inc. is priced for free-cash-flow growth of about 11.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $38.32M from the FY ending 2025-09-30). For comparison, revenue 8.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Azenta, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.